MX2013010446A - Regimenes de dosificacion para el tratamiento de la enfermedad de fabry. - Google Patents

Regimenes de dosificacion para el tratamiento de la enfermedad de fabry.

Info

Publication number
MX2013010446A
MX2013010446A MX2013010446A MX2013010446A MX2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A MX 2013010446 A MX2013010446 A MX 2013010446A
Authority
MX
Mexico
Prior art keywords
treatment
fabry disease
dosing regimens
subject matter
disclosed subject
Prior art date
Application number
MX2013010446A
Other languages
English (en)
Spanish (es)
Inventor
Douglas Stuart Greene
Kenneth Joseph Valenzano
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46831259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013010446(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2013010446A publication Critical patent/MX2013010446A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01062—Glycosylceramidase (3.2.1.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
MX2013010446A 2011-03-11 2012-03-08 Regimenes de dosificacion para el tratamiento de la enfermedad de fabry. MX2013010446A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161451798P 2011-03-11 2011-03-11
US201161578201P 2011-12-20 2011-12-20
US201261596165P 2012-02-07 2012-02-07
PCT/US2012/028260 WO2012125402A2 (en) 2011-03-11 2012-03-08 Dosing regimens for the treatment of fabry disease

Publications (1)

Publication Number Publication Date
MX2013010446A true MX2013010446A (es) 2014-03-27

Family

ID=46831259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010446A MX2013010446A (es) 2011-03-11 2012-03-08 Regimenes de dosificacion para el tratamiento de la enfermedad de fabry.

Country Status (16)

Country Link
US (4) US20140219986A1 (show.php)
EP (2) EP3698792A1 (show.php)
JP (5) JP2014528901A (show.php)
KR (1) KR20140011367A (show.php)
CN (2) CN103974619B (show.php)
AU (6) AU2012229330B2 (show.php)
CA (1) CA2829947C (show.php)
CL (1) CL2013002601A1 (show.php)
EA (1) EA031874B1 (show.php)
ES (1) ES2807502T3 (show.php)
HK (1) HK1242998A1 (show.php)
MX (1) MX2013010446A (show.php)
SG (2) SG10201604757RA (show.php)
TW (3) TWI624258B (show.php)
WO (1) WO2012125402A2 (show.php)
ZA (1) ZA201306735B (show.php)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4541418A3 (en) 2006-05-16 2025-07-09 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
PL2252313T3 (pl) 2008-02-12 2015-09-30 Amicus Therapeutics Inc Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
WO2014164503A1 (en) 2013-03-11 2014-10-09 Genzyme Corporation Hyperglycosylated binding polypeptides
RU2016137120A (ru) * 2014-02-17 2018-03-22 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Микробиологический способ
CN116333148A (zh) 2014-03-19 2023-06-27 建新公司 靶向模块的位点特异性糖工程化
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
US10874355B2 (en) 2014-04-24 2020-12-29 Cognoa, Inc. Methods and apparatus to determine developmental progress with artificial intelligence and user input
GB201508025D0 (en) * 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
EP3432882B1 (en) * 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
US12070453B2 (en) * 2016-07-19 2024-08-27 Amicus Therapeutics, Inc. Treatment of Fabry disease in ERT-naïve and ERT-experienced patients
JP7182554B2 (ja) 2016-11-14 2022-12-02 コグノア，インク． 発達に係る疾病を評価し、およびカバー率と信頼度に対する制御を提供する方法および装置
WO2018148365A1 (en) * 2017-02-09 2018-08-16 Cognoa, Inc. Platform and system for digital personalized medicine
MX391565B (es) 2017-05-30 2025-03-21 Amicus Therapeutics Inc Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
TWI795408B (zh) * 2017-05-30 2023-03-11 美商阿米庫斯醫療股份有限公司 治療有腎損傷的法布里患者的方法
JP7066157B2 (ja) 2017-06-14 2022-05-13 学校法人 明治薬科大学 ファブリー病治療用医薬の組合せ物及びその利用
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
CA3110065A1 (en) * 2018-08-20 2020-02-27 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
CN113873935B (zh) 2019-03-22 2024-11-22 科格诺亚公司 个性化数字化治疗方法和装置
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
EA202290024A1 (ru) * 2019-06-11 2022-03-14 Амикус Терапьютикс, Инк. Способы лечения болезни фабри у пациентов с почечной недостаточностью
EP3851105A3 (en) 2019-08-07 2021-10-13 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics
US20240197706A1 (en) * 2022-12-13 2024-06-20 Amicus Therapeutics, Inc. Methods of improving the pharmacokinetics of migalastat

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551177A (en) * 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US6274597B1 (en) * 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
ES2531478T3 (es) * 2003-01-31 2015-03-16 The Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
CN100457106C (zh) * 2005-06-15 2009-02-04 同济大学 1-脱氧野尻霉素在制备治疗糖尿病肾病药物中的应用
EP4541418A3 (en) * 2006-05-16 2025-07-09 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
WO2008121826A2 (en) * 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
MX2009011473A (es) * 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US20100291060A1 (en) * 2007-08-29 2010-11-18 Shire Human Genetic Therapies, Inc Subcutaneous administration of alpha-galactosidase a

Also Published As

Publication number Publication date
JP2020033360A (ja) 2020-03-05
SG193379A1 (en) 2013-10-30
TW201634048A (zh) 2016-10-01
CN103974619A (zh) 2014-08-06
US20180153999A1 (en) 2018-06-07
CL2013002601A1 (es) 2014-03-28
KR20140011367A (ko) 2014-01-28
AU2016204445B2 (en) 2018-03-22
WO2012125402A3 (en) 2014-05-01
CA2829947C (en) 2019-01-15
EP3698792A1 (en) 2020-08-26
JP2014528901A (ja) 2014-10-30
TW201302197A (zh) 2013-01-16
AU2022203011A1 (en) 2022-05-26
AU2024205251A1 (en) 2024-08-22
EP2683382A2 (en) 2014-01-15
US20200268890A1 (en) 2020-08-27
EP2683382B1 (en) 2020-04-22
AU2018201637A1 (en) 2018-04-05
TWI624258B (zh) 2018-05-21
AU2012229330B2 (en) 2016-04-21
AU2012229330A1 (en) 2013-10-03
AU2020201715A1 (en) 2020-04-09
CA2829947A1 (en) 2012-09-20
TW201740945A (zh) 2017-12-01
WO2012125402A2 (en) 2012-09-20
EP2683382A4 (en) 2014-10-22
EA031874B1 (ru) 2019-03-29
CN103974619B (zh) 2017-02-15
HK1242998A1 (zh) 2018-07-06
ZA201306735B (en) 2014-07-30
JP2023093448A (ja) 2023-07-04
EA201301018A1 (ru) 2014-04-30
JP2021098697A (ja) 2021-07-01
JP2017132780A (ja) 2017-08-03
US20240115708A1 (en) 2024-04-11
ES2807502T3 (es) 2021-02-23
CN107088225A (zh) 2017-08-25
SG10201604757RA (en) 2016-08-30
AU2016204445A1 (en) 2016-07-21
TWI624259B (zh) 2018-05-21
NZ615726A (en) 2015-01-30
US20140219986A1 (en) 2014-08-07

Similar Documents

Publication Publication Date Title
MX2013010446A (es) Regimenes de dosificacion para el tratamiento de la enfermedad de fabry.
CY1124135T1 (el) Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
GB201111485D0 (en) Drug composition and its use in therapy
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
PT2470199T (pt) Terapia de substituição enzimática com escaladas de dose para tratamento de deficência em esfingomielinase ácida
MX2013009764A (es) Moduladores de receptores canabinoides.
NZ702469A (en) Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
IL260078B (en) Therapy used to treat Gaucher disease
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
MX2013010947A (es) Complejos de galio, composiciones farmacéuticas y métodos de uso.
UA70710U (ru) Способ профилактики рецидивов аллергодерматозов у больных с вторичными иммунодефицитными состояниями
EP2692351A4 (en) ACTIVE FRACTION OF PAULLINIA CUPANA WITH IMPROVED EFFICACY AGAINST TEMPTATION, PROCESS FOR PREPARING AN ACTIVE FRACTION, USE THEREOF, PHARMACEUTICAL COMPOSITION, MEDICAMENTS AND TREATMENT FOR TREATMENT
UA65037U (ru) Способ лечения взрослых больных с соматоформными расстройствами
UA72002U (ru) Способ коррекции показателей системы фагоцитирующих макрофагов у больных туберкулезом легких
UA70775U (ru) Способ лечения менингококцемии у детей
UA64067U (ru) Способ лечения больных синдромом стивена-джонсона
UA65038U (ru) Способ лечения больных послеродовыми психозами
UA52520U (ru) Способ лечения нарушений функционального состояния кишечника у новорожденных и детей младенческого возраста
UA59700U (ru) Способ лечения метаболического синдрома
UA69683U (ru) Способ лечения больных стеатогепатитом
UA33199U (ru) Способ коррекции показателей клеточного звена иммунитета у больных с соматоформными депрессивными расстройствами
UA33198U (ru) Способ коррекции иммунокомплексного спектра крови у больных соматоформными депрессивными расстройствами
UA50311U (ru) Способ лечения хронического гиперацидного гастродуоденита у детей